#invitae

It didn’t take long to discover that companies like Invitae exist where genetic panels can be ordered by doctors and results can be obtained by those who don’t have access to a geneticist. They also include genetic counseling and take care of the billing.

Obviously Fastly was a clear winner and doesn’t look to slow down anytime soon, but it’s about consistently finding new companies to hold for the long-term. As mentioned in the last post, I started off with Fastly, Crowdstrike, Livongo, Zoom, and Datadog, but these were not paying off despite my conviction for them. I focused on finding better ways and resources for companies.

I first went to Reddit, which was a clear vacuum for bad investing decisions, but it showed me that we were all looking for the same companies. I just was not focused on buying 3-million-dollar marijuana stocks.  I checked out CNBC and YouTube and found at that these platforms were focused on only entertainment and not sound advice. My college days of economics have proven quite useful when it comes to the market and it’s easy to tell when Youtubers or CNBC people are using talking points from the previous decades. Finally, I focused on Twitter. Twitter has got to be the best social platform for stock tips. No one get’s paid for memberships like YouTube. Even with a shade of anonymity, it’s not like Reddit, because validation can be built around people who follow these certain people. Famous investors and economists won’t typically follow some random person when they have no obligation to.

So, I turned to Twitter and simply used their search function. I focused on finding like-minded investors. I simply searched by stock symbol of my current holdings, for example, I would search ‘$FSLY’ and I would see anyone who was talking about Fastly from an investors point of view. I found people who would break down these companies and examine their growth prospects and much more. I followed as many people as I could and just researched all their tweets on companies. I would take those companies stock symbols and do searches on those companies and I just gathered as much as I could. I finally relaxed and realized I had gathered 130+ companies worthy of investing in.

I took these companies and screened them by IPO date, revenue growth rates, market capitalization and narrowed it down to about 30 companies I thought fit my criteria. I just had to believe in a future where they were highly valued as a company. Just like Fastly, I had to watch hours upon hours of conferences and interviews and commercials on these companies. I eventually got to a gene company called Invitae (NVTA), which surprised me because I was sure that only e-commerce and SaaS tech companies would make my list.

I read and watched so many presentations on this company, but I didn’t feel the same passion for it as my original growth companies. I went to twitter to see if maybe I missed some great tweets about this company, but I only found the earlier mentions as before. No deep dives or hard selling points, but it seemed like everyone was aware of $NVTA.

February 6, 2020 – Invitae (NVTA) $22.39 a share

I finally purchased a few NVTA shares, but I still felt like I was just investing with a wave of people, instead of truly believing in this company. I needed to be convinced. I was already however convinced (as I am still today) that I needed no experience with technical stock analyst, chart reading, ratios, or headlines. I needed only a story. I vision of my companies being needed in the future. This is how I found Cathie Woods and Ark Invest.

I was watching CNBC one morning and Tesla was like a couple hundred bucks a share. They had this portfolio manager come on and she was marvelous. She was not a paid contributor to the network, and it was so obvious. She was talking about how Tesla was going to be the largest company in the world and worth trillions. She said essentially all the rating agencies and bankers were wrong and could not get out of the way of conventionally thinking. Tesla was not a car company. It was much more, and she laid out a plan so convincing I bought 4 shares of it at the time. I was blown away. The main thing for me was not what she was saying, but that the other analyst was laughing at her ideas, but you could see on her face that she knew she was right. So, I decided to research her fund and look at what other companies she invests in…  Tesla was number one, but $1B Invitae was number two by miles. I knew I would find my convincing through Cathie and her team at Ark Invest.

I watched her conferences and read her thoughts on the future of this company and how it was so clear… Invitae was going to be big. Throughout the crash, the stock plummeting on concerns of people using their services. I too was concerned, but I still donated plasma which was not important… besides what I heard one day giving plasma. A few of the girls at the plasma center were raving about these tests they took prior to deciding on having kids and all sorts of things. I had a feeling. I just knew. I asked, “what company was that with. Sorry for intruding.”

Invitae.

Shares closed at $11 a share that day and I had increased my position.

NVTA is now $47 a share and a 8.32-Billion-dollar company. Still incredibly early.

In this three-part write-up, I am not focusing on what the companies truly do. There won’t be deep dives in these posts. It is simply a story of how you don’t need to know how to read charts and day trades to make money in the stock market. It may seem like you need to know about charts and price to earning ratios and so much other noise, but you don’t. Find companies that are growing. Learn about them inside and out. Follow their stories.

Overview of Global Triple X Syndrome Treatment Market:

The Global Triple X Syndrome Treatment Market report is a skilful and deep analysis of the present situation and challenges. This report focuses on the key drivers, restraints, Market opportunities, threats and risks for Market major players. It makes available analysis of Market size, shares, growth, segmentation, revenue projection (USD Mn), and regional study till 2027. Analysis and discussion of important industry trends, Market size, Market share estimates are mentioned in the report. Triple X Syndrome Treatment Market research document also conducts study on production capacity, consumption, import and export for all major regions across the globe.

The reliable Triple X Syndrome Treatment Market report offers a comprehensive overview of the global Market and contains thoughtful insights, facts, historical information, and statistically supported and industry-verified Market data. It also encompasses forecasts using a suitable set of predictions and distinct research methodologies. This industry report is a professional in-depth study on the current state of the Market. The Market report also contains the drivers and restraints for the Triple X Syndrome Treatment Market that are derived from SOWT analysis, and also shows what all the recent developments, product launches, joint ventures, mergers and acquisitions by the several key players and brands that are driving the Market by systemic company profiles.

Get Sample Report + All Related Graphs & Charts @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-triple-x-syndrome-treatment-market .

The Global Triple X Syndrome Treatment Market is expected to gain market growth at a healthy CAGR in the forecast period of 2020 to 2027.

According to market research study, Triple X Syndrome is a rare genetic disorder characterized by chromosomal abnormality. It affects about 1 in 1000 females. The normal number of X chromosomes present in females in two but the person affected with triple X syndrome has three X chromosomes. These abnormalities in female leads to developmental delays in body and even learning abilities can be affected extensively. The kidney function also gets disrupt and the mall age numbers are more likely to face the complications. The signs and symptoms associated with triple X syndrome vary gently among girls and women.

The most significant key factors driving the growth of the Global Triple X Syndrome Treatment Market are rising prevalence of triple X syndrome associated cases in females.

Top Leading Key Manufacturers are: Centogene AG, Eurofins Scientific, Hoffmann-La Roche Ltd., Invitae Corporation, LLumina Inc, Natera Inc, Progenity Inc, perkin Elmer Inc, Quest Diagnostic, Lifecodexx AG, Ravgen Inc and Sequenom Inc and others. New product launches and continuous technological innovations are the key strategies adopted by the major players.

In terms of the geographic analysis, North America has the largest market share as the presence of key manufacturers of the product is high and, increasing research and development activities, healthcare expenditure contributes in raising the significant growth of the market. APAC is expected to grow in the over coming years due to increased new research and developments on triple X syndrome treatment market.

Overview of Global Nanomedicine Market:

According to the world class Nanomedicine Market report, the leading players are focusing more on offering products at rational prices to gain a competitive advantage over the other players in the Healthcare industry. The main objective of this exploratory study is to provide a clear picture and a better understanding of the market to the suppliers, manufacturers, and distributors. With an excellent Nanomedicine market report businesses can create a unique space in the global industry and get identified as the most consistent and dedicated growth partner for market research, strategy formulation and sustainable development of organization.

The Global Nanomedicine Market Is Expected To Witness Market Growth At A Rate Of 12.7% In The Forecast Period Of 2021 To 2028.

Available Exclusive Sample Copy of this Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-nanomedicine-market&paragp .

As per the market analysis, Nanomedicine Is Known To Be One Of The Applications Of Nanotechnology That Is Utilized In The Diagnosis, Treatment, Monitoring, And Control Of Biological Systems. Nanomedicine Utilizes Nanoscale Manipulation Of Materials To Augment Medicine Delivery. Therefore, Nanomedicine Has Enabled The Treatment Of Several Diseases. Nanomedicine Is In The Budding Stage, As Various Products Are In The Development Phase.

Some of the most important key factors driving the Global Nanomedicine Market are advancing technologies for drug delivery, rise in the acceptance of nanomedicine across diverse applications, and increase in government support and funding.

Top Leading Key Manufacturers are: Abbott, Invitae Corporation, General Electric Company, Leadiant Biosciences, Inc., Johnson & Johnson Services, Inc., Mallinckrodt, Merck Sharp & Dohme Corp., Nanosphere Health Sciences, Inc., Pfizer Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., Gilead Sciences, Inc., Amgen Inc., Bristol-Myers Squibb Company, Abbvie Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Luminex Corporation, Lilly, Nanobiotix, Sanofi, UCB S.A., Ablynx and others. New product launches and continuous technological innovations are the key strategies adopted by the major players.

In terms of the geographic analysis, North America Dominates The Nanomedicine Market Due To The Occurrence Of The Growing Partnerships Between Enterprises Operating Herein And Nanomedicine Startup Organizations. Furthermore, The Support From The Government Entities And The Rise In The Research And Development Expenditure Will Further Boost The Growth Of The Nanomedicine Market In The Region During The Forecast Period. Asia-Pacific Is Projected To Observe A Significant Amount Of Growth In The Nanomedicine Market Due To The Increase In The Number Of Research Grants. Moreover, The Growing Number Of Venture Capital Investors From The Advancing Countries Is Further Anticipated To Propel The Growth Of The Nanomedicine Market In The Region In The Coming Years.

Zoom Video, Stitch Fix, Invitae

Zoom CEO Eric Yuan speaks before the Nasdaq opening bell ceremony in New York on April 18, 2019. Kena Betancur | Getty Images Check out the companies making headlines after the bell on Monday: Zoom Video – Zoom stock fell 1.3% after The Wall Street Journal reported that founder Eric Yuan transferred roughly 40% of his stake in the company to two unspecified recipients. The stake is valued at…